US pharmaceutical giant Pfizer could make a hostile bid for AstraZeneca as early as today.
Its £63 billion takeover offer was rejected after the UK company said it "substantially" undervalued the business.
That has forced Pfizer to consider its next move, with industry experts believing a hostile bid - which would aim to bypass the AstraZeneca management and target shareholders directly - could come soon.
Last week, Pfizer insisted it was committed to building a research and development hub in Cambridge which was planned by AstraZeneca.
The £300m base at the Cambridge Biomedial Campus would house about 2,000 researchers.
But a hostile bid would trigger increased calls for the offer to be referred to the competition authorities and would also heighten union fears over jobs if the takeover was successful.
More top news
Heavy showers will continue in places overnight and it will feel muggy. Tomorrow, showers clear early on and it will be a sunny day.
A transformation from gravel pits to grebe habitat, a quarry in Cambridgeshire that's slowly being turned into Britain's biggest reed bed.
A teenager who was given just days to live in 2013 has picked up his GCSE results today.